Abivax S.A. Stock
Price
Target price
€9.95
€9.95
-4.450%
-0.46
-4.450%
-
01.10.24 / Tradegate
WKN: A14UQC / Name: Abivax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Abivax
sharewise wants to provide you with the best news and tools for Abivax, so we directly link to the best financial data sources.
Financials
News
EQS-News: Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
EQS-News: Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
EQS-News: Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model
EQS-News: Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model
EQS-News: Abivax presents first-half 2024 financial results
EQS-News: Abivax presents first-half 2024 financial results
EQS-News: Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
EQS-News: Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
EQS-News: Abivax Provides Operational and Key Program Update
EQS-News: Abivax Provides Operational and Key Program Update
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies
EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies